Pulmonary Pharmacology & Therapeutics

Pulmonary Pharmacology & Therapeutics - ISSN 1094-5539
Source Normalized Impact per Paper (SNIP): 0.986 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 1.061 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Impact Factor: 3.41 (2020) Impact Factor:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
5 Year Impact Factor: 3.283 (2020) Five-Year Impact Factor:
To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
Volumes: Volume 6
Issues: 6 issues
ISSN: 10945539
Editor-in-Chief: Cormet-Boyaka

Institutional Subscription

Sales tax will be calculated at check-out Price includes VAT/GST

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.

Research Areas Include:

All major diseases of the lung
Drug delivery
Pulmonary Toxicology

Before submitting, please note the "Rules of 5" defining immediate rejection criteria of PPT:

1. Out of scope: The paper should report on the use of pharmacological or toxicological studies (positive or negative) that are directly related to Pulmonary Pharmacology & Therapeutics.

Immediate rejection criteria are:
a) Testing of extracts or plant parts that are not characterized
b) Case Reports or n=1 studies

2. Too preliminary: A paper must be based on a thorough and extensive study, using proper controls

Immediate rejection criteria are:
a) In vitro studies with a single dose, or very high concentration b) Single dose studies with very few animals, no dose-response studies c) No proper controls. d) Repetition or confirmation of an earlier work

3. Unethical: The study must have been carried under appropriate ethical approval for the study (either animal or human).

4. Inappropriate experiments or lacking essential detail

Immediate rejection criteria are: a) Wrong species or lacking details on the exact number of animals/subjects used
b) No details of structure if a new drug is used for the first time

5. Lack of novelty: The study must represent a novel approach to the field.

Immediate rejection criteria are:
a) Repetition of well known data
b) No advance of knowledge in the field

Note that only manuscripts written in good English will be considered by the Editors (British usage is preferred).